Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Eribulin | Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Uses: Scientific research. Group: Signaling pathways. Alternative Names: B1939; E7389; ER-086526. CAS No. 253128-41-5. Pack Sizes: 10 mM * 1 mL; 500 μg; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13442. |  |
| Eribulin | Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21%, the time spent paused increased 67%, and dynamicity decreased 35% (but without reduction in mean centromere separation), indicating that eribulin decreased normal microtubule-dependent spindle tension at the kinetochores, preventing the signal for mitotic checkpoint passage. [(3)H]eribulin binds soluble tubulin at a single site; however, this binding is complex with an overall K(d) of 46 microM, but also showing a real or apparent very high affinity (K(d) = 0.4 microM) for a subset of 25% of the tubulin. Eribulin also binds microtubules with a maximum stoichiometry of 14.7 +/- 1.3 molecules per microtubule (K(d) = 3.5 microM), strongly suggesting the presence of a relatively high-affinity binding site at microtubule ends. At 100 nM, the concentration that inhibits microtubule plus end growth by 50%, we found that one molecule of eribulin is bound per two microtubules, indicating that the binding of a single eribulin molecule at a microtubule end can potently inhibit its growth. Eribulin does not suppress dynamic instability at microtubule minus ends. Eribulin's in vivo superiority derives from its ability to induce irreversible mitotic blockade, which appears related to persistent drug retention and sustained Bcl-2 phosphorylation. Synonyms: Halaven; B1939; E7389; ER-0 |  |
| Eribulin Impurity 1 | Eribulin Impurity 1. Uses: For analytical and research use. Group: Impurity standards. Alternative Names: methyl 3-(trimethylsilyl)pent-4-enoate. CAS No. 185411-12-5. Molecular formula: C9H18O2Si. Mole weight: 186.32. Catalog: APB185411125. |  |
| Eribulin Impurity 10 | Eribulin Impurity 10. Uses: For analytical and research use. Group: Impurity standards. Alternative Names: Eribulin Impurity 10. CAS No. 1534341-95-1. Molecular formula: C40H59NO11. Mole weight: 729.90. Catalog: APB1534341951. | |
| Eribulin mesylate | Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Uses: Scientific research. Group: Signaling pathways. Alternative Names: B1939 mesylate; E7389 mesylate; ER-086526 mesylate. CAS No. 441045-17-6. Pack Sizes: 500 μg; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13442A. | |
| Eribulin Mesylate | Eribulin Mesylate is an antitumor drug that can be used to treat patients with metastatic breast cancer. It inhibits the proliferation of cancer cells by binding tubulin and microtubules. Eribulin Mesylate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Uses: The treatmnet of breast cancer. Synonyms: 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (1:1); 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt); E 7389 methanesulfonate; Halaven; Eribulin monomethanesulfonate. Grade: ≥95%. CAS No. 441045-17-6. Molecular formula: C41H63NO14S. Mole weight: 826.01. | |
| Farletuzumab ecteribulin | Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: MORAb-202. CAS No. 2407465-18-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99612. | |
| Balixafortide | Balixafortide is a potent and selective antagonist of the chemokine receptor CXCR4. The combination of balixafortide and eribulin was previously granted a fast track designation for the treatment of HER2-negative metastatic breast cancer in patients who have received at least 2 prior lines of chemotherapy in the metastatic setting by the FDA in 2018. Synonyms: POL6326. Grade: >98%. CAS No. 1051366-32-5. Molecular formula: C84H118N24O21S2. Mole weight: 1864.11. | |
Our database is helping our users find suppliers everyday.
